New drug trial targets Hard-to-Treat HER2 cancers
NCT ID NCT06500052
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug called BL-M17D1 in people with advanced HER2-positive or low-HER2 gastrointestinal cancers and other solid tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 20 adults will take part, and the study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.